Trial Profile

An Open-Label Extension Study of Edasalonexent in Pediatric Patients With Duchenne Muscular Dystrophy

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 26 Jul 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Edasalonexent (Primary)
Indications Duchenne muscular dystrophy
Focus Adverse reactions; Registrational
Acronyms GalaxyDMD
Sponsors Astria Therapeutics

Most Recent Events

14 Nov 2020 This trial has been discontinued in Sweden according to European Clinical Trials Database record.
12 Nov 2020 According to a Catabasis Pharmaceuticals media release, as the PolarisDMD trial did not meet the primary endpoint and secondary endpoint timed function tests also did not show statistically significant improvements, the company is stopping activities related to the development of edasalonexent, including this study.
12 Nov 2020 Status changed from recruiting to discontinued, according to a Catabasis Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com